Samudio Ismael, Konopleva Marina, Carter Bing, Andreeff Michael
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Cancer Treat Res. 2010;145:197-217. doi: 10.1007/978-0-387-69259-3_12.
Nearly 25 years after the seminal publication of John Foxton Kerr that first described apoptosis, the process of regulated cell death, our understanding of this basic physiological phenomenon is far from complete [39]. From cardiovascular disease to cancer, apoptosis has assumed a central role with broad ranging therapeutic implications that depend on a complete understanding of this process, yet have also identified an incredibly complex regulatory system that is critical for development and is at the core of many diseases, challenging scientist and clinicians to step into its molecular realm and modulate its circuitry for therapeutic purposes. This chapter will review our understanding of the molecular circuitry that controls apoptosis in leukemia and the pharmacological manipulations of this pathway that may yield therapeutic benefit.
在约翰·福克森·克尔首次描述细胞凋亡（即程序性细胞死亡过程）的开创性论文发表近25年后，我们对这一基本生理现象的理解仍远未完善[39]。从心血管疾病到癌症，细胞凋亡都发挥着核心作用，具有广泛的治疗意义，这既依赖于对该过程的全面理解，同时也揭示了一个极其复杂的调控系统，该系统对发育至关重要，并且是许多疾病的核心，这促使科学家和临床医生深入其分子领域，为治疗目的调节其信号通路。本章将综述我们对控制白血病中细胞凋亡的分子信号通路的理解，以及对该通路进行药理学操纵可能带来的治疗益处。
